Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
In the US, Gilead charges around $44 000 per patient per year for lenacapavir treatment4—a price that is unaffordable to low and middle income countries. It also missed out an important group of middle income countries: Argentina, Brazil, Mexico, and Peru. Gilead missed a great opportunity to invest in and strengthen local manufacturing in the region where its trial was conducted and in countries with the highest burden of HIV. Gilead chose these four countries for its Purpose-2 trial based on their HIV incidence, especially in sexual and gender minorities. Tackling the middle income dilemma has become one of the most urgent, pressing imatters in the United Nations’ goal of ending AIDS by 2030.
Source: New York Times October 14, 2024 15:19 UTC
